Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0HLZRS
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
3G10-TG6-vc0101
|
|||||
| Synonyms |
3G10 TG6 vc0101
Click to Show/Hide
|
|||||
| Organization |
Pfizer Inc.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 4 Indication(s)
Adult T acute lymphoblastic leukemia [ICD11:2A90]
Investigative
Burkitt lymphoma [ICD11:2A85]
Investigative
Mature T-cell lymphoma [ICD11:2A90] [ICD11:2A90]
Investigative
Plasma cell myeloma [ICD11: 2A83]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
1.86
|
|||||
| Antibody Name |
3G10-TG6
|
Antibody Info | ||||
| Antigen Name |
C-X-C chemokine receptor type 4 (CXCR4)
|
Antigen Info | ||||
| Payload Name |
Auristatin 0101
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 61.00% (Day 21) | Positive CXCR4 expression (CXCR4+++/++) | ||
| Method Description |
Mice were treated with a single intravenous dose of the ADCs at 1.5 mg/kg.
|
||||
| In Vivo Model | Ramos CDX model | ||||
| In Vitro Model | Burkitt lymphoma | Ramos cells | CVCL_0597 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 82.80% (Day 27) | Positive CXCR4 expression (CXCR4+++/++) | ||
| Method Description |
Mice were treated with a single intravenous dose of the ADCs at 1.5 mg/kg.
|
||||
| In Vivo Model | HPB-ALL CDX model | ||||
| In Vitro Model | T acute lymphoblastic leukemia | HPB-ALL cells | CVCL_1820 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 92.90% (Day 21) | Positive CXCR4 expression (CXCR4+++/++) | ||
| Method Description |
Mice were treated with a single intravenous dose of the ADCs at 3 mg/kg.
|
||||
| In Vivo Model | Ramos CDX model | ||||
| In Vitro Model | Burkitt lymphoma | Ramos cells | CVCL_0597 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 93.00% (Day 27) | Positive CXCR4 expression (CXCR4+++/++) | ||
| Method Description |
Mice were treated with a single intravenous dose of the ADCs at 3 mg/kg.
|
||||
| In Vivo Model | HPB-ALL CDX model | ||||
| In Vitro Model | T acute lymphoblastic leukemia | HPB-ALL cells | CVCL_1820 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 99.00% (Day 21) | Positive CXCR4 expression (CXCR4+++/++) | ||
| Method Description |
Mice were treated with a single intravenous dose of the ADCs at 6 mg/kg.
|
||||
| In Vivo Model | HPB-ALL CDX model | ||||
| In Vitro Model | T acute lymphoblastic leukemia | HPB-ALL cells | CVCL_1820 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% (Day 21) | Positive CXCR4 expression (CXCR4+++/++) | ||
| Method Description |
Mice were treated with a single intravenous dose of the ADCs at 6 mg/kg.
|
||||
| In Vivo Model | Ramos CDX model | ||||
| In Vitro Model | Burkitt lymphoma | Ramos cells | CVCL_0597 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.05 nM | Positive CXCR4 expression (CXCR4+++/++) | ||
| Method Description |
Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
|
||||
| In Vitro Model | Plasma cell myeloma | MOLP-8 cells | CVCL_2124 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.06 nM | Positive CXCR4 expression (CXCR4+++/++) | ||
| Method Description |
Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
|
||||
| In Vitro Model | T acute lymphoblastic leukemia | HPB-ALL cells | CVCL_1820 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.06 nM | Positive CXCR4 expression (CXCR4+++/++) | ||
| Method Description |
Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
|
||||
| In Vitro Model | Adult T acute lymphoblastic leukemia | MOLT-4 cells | CVCL_0013 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.14 nM | Positive CXCR4 expression (CXCR4+++/++) | ||
| Method Description |
Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
|
||||
| In Vitro Model | Plasma cell myeloma | RPMI-8226 cells | CVCL_0014 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 1.86 nM | Positive CXCR4 expression (CXCR4+++/++) | ||
| Method Description |
Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
|
||||
| In Vitro Model | Burkitt lymphoma | Ramos cells | CVCL_0597 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 8.53 nM | Positive CXCR4 expression (CXCR4+++/++) | ||
| Method Description |
Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
|
||||
| In Vitro Model | Plasma cell myeloma | MM1.S cells | CVCL_8792 | ||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.